Skip To Main Content
Ruhina Maeshima on Muck Rack

Ruhina Maeshima

As seen in: Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ruhina

Contact Ruhina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ultrasound-guided renal artery administration of angiopoietin-1 RNA therapy slows the progression of preclinical WT1 glomerular disease

|
By Kimberly A. Dowd, Huaxin Song, Saif Malik, Jennifer Chandler, Ruhina Maeshima, Maria Kolatsi-Joannou, William Mason, Lauren Russell, Shunping Han, Daniyal J Jafree, Emily Moore, Reem Al-Saadi, Kathy Pritchard-Jones, Daniel Stuckey, Andrew V. Benest, David Bates, Paul Winyard, Luigi Gnudi, Stephen Hart, Tammy L. Kalber, David Long, Yanis Harfouche, Hanna Gautier, Christina Katsiva, Aoife M. Waters
| Science Magazine Verified
Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary Congenital glomerular disease caused by mutations in the Wilms Tumor 1 (WT1) gene currently has no curative therapy. Malik et al. developed a lipid nanocomplex approach to test a potential podocyte- and glomerular endothelial cell–targeted therapy for WT1-mediated glomerulopathy.
Open in Who Shared Issue with article?

Integrin‐Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor‐Specific Delivery Achieve MYCN Silencing with Improved Survival

|
By Aristides D Tagalakis, Kin Ho, Vignesh Jayarajan, Ruhina Maeshima
| Wiley Online Library Verified
Abstract The authors aim to develop siRNA therapeutics for cancer that can be administered systemically to target tumors and retard their growth. The efficacy of systemic delivery of siRNA to tumors with nanoparticles based on lipids or polymers is often compromised by their rapid clearance from the circulation by the liver.
Open in Who Shared Issue with article?
See all 2 articles